Carolien Nienke Heleen Abheiden1, Alexandra Vera Ruth van Reuler2, Wessel Willem Fuijkschot3, Johanna Inge Petra de Vries4, Abel Thijs5, Marjon Alina de Boer6. 1. Department of Obstetrics and Gynecology, Institute for Cardiovascular Research (ICaR-VU), VU University Medical Center, P.O. Box 7057, 1007 MB Amsterdam, The Netherlands. Electronic address: c.abheiden@vumc.nl. 2. Department of Obstetrics and Gynecology, Institute for Cardiovascular Research (ICaR-VU), VU University Medical Center, P.O. Box 7057, 1007 MB Amsterdam, The Netherlands. Electronic address: a.vanreuler@vumc.nl. 3. Department of Internal Medicine, Institute for Cardiovascular Research (ICaR-VU), VU University Medical Center, P.O. Box 7057, 1007 MB Amsterdam, The Netherlands. Electronic address: w.fuijkschot@vumc.nl. 4. Department of Obstetrics and Gynecology, Institute for Cardiovascular Research (ICaR-VU), VU University Medical Center, P.O. Box 7057, 1007 MB Amsterdam, The Netherlands. Electronic address: jip.devries@vumc.nl. 5. Department of Internal Medicine, Institute for Cardiovascular Research (ICaR-VU), VU University Medical Center, P.O. Box 7057, 1007 MB Amsterdam, The Netherlands. Electronic address: a.thijs@vumc.nl. 6. Department of Obstetrics and Gynecology, Institute for Cardiovascular Research (ICaR-VU), VU University Medical Center, P.O. Box 7057, 1007 MB Amsterdam, The Netherlands. Electronic address: m.deboer2@vumc.nl.
Abstract
OBJECTIVE: Aspirin reduces the risk of recurrent hypertensive disorders of pregnancy (HD) and fetal growth restriction (FGR). This study examined the non-adherence rates of aspirin in women with high-risk pregnancies. STUDY DESIGN: All consecutive women between 24 and 36weeks gestation with an indication for aspirin use during pregnancy were invited for this study. A survey was used which included two validated questionnaires, the simplified medication adherence questionnaire (SMAQ) and the Beliefs and Behaviour Questionnaire (BBQ). MAIN OUTCOME MEASURES: To determine the non-adherence rates of aspirin, and to identify the beliefs and behavior concerning aspirin. RESULTS: Indications for aspirin use during pregnancy were previous HD, FGR, intrauterine fetal death or current maternal disease. Non-adherence rates according to the SMAQ and BBQ were 46.3% and 21.4% respectively. No differences in demographic background or obstetrical characteristics between adherent and non-adherent women could be demonstrated. CONCLUSIONS: Adherence for aspirin in this high-risk population cannot be taken for granted. The non-adherence rates in pregnant women are comparable with the non-adherence rates for aspirin in the non-pregnant population.
OBJECTIVE:Aspirin reduces the risk of recurrent hypertensive disorders of pregnancy (HD) and fetal growth restriction (FGR). This study examined the non-adherence rates of aspirin in women with high-risk pregnancies. STUDY DESIGN: All consecutive women between 24 and 36weeks gestation with an indication for aspirin use during pregnancy were invited for this study. A survey was used which included two validated questionnaires, the simplified medication adherence questionnaire (SMAQ) and the Beliefs and Behaviour Questionnaire (BBQ). MAIN OUTCOME MEASURES: To determine the non-adherence rates of aspirin, and to identify the beliefs and behavior concerning aspirin. RESULTS: Indications for aspirin use during pregnancy were previous HD, FGR, intrauterine fetal death or current maternal disease. Non-adherence rates according to the SMAQ and BBQ were 46.3% and 21.4% respectively. No differences in demographic background or obstetrical characteristics between adherent and non-adherent women could be demonstrated. CONCLUSIONS: Adherence for aspirin in this high-risk population cannot be taken for granted. The non-adherence rates in pregnant women are comparable with the non-adherence rates for aspirin in the non-pregnant population.
Authors: Jeske Milou Bij de Weg; Laura Visser; Martijn Alexander Oudijk; Johanna Inge Petra de Vries; Christianne Johanna Maria de Groot; Marjon Alina de Boer Journal: PLoS One Date: 2022-06-09 Impact factor: 3.752